- Home - Valneva
Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need
- About Us - Valneva
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs
- R D - Valneva
Our R D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines
- Valneva Receives Marketing Authorization in Europe for Inactivated . . .
The European Commission has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age
- About Us - Valneva
Valneva est une société spécialisée dans le développement, la production et la commercialisation de vaccins prophylactiques contre des maladies infectieuses générant d’importants besoins médicaux
- Valneva Announces European Commission Approval of Advance Purchase . . .
Saint-Herblain (France), November 10, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (“EC”) has approved an agreement pursuant to which Valneva would supply up to 60 million doses of VLA2001, its inactivated COVID-19 vaccine candidate, over two years including approximately 27 million doses in […]
- Valneva Announces U. S. FDA Approval of World’s First Chikungunya . . .
The U S Food and Drug Administration (FDA) has approved IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV
- Investors - Valneva
Investor Relations Team Campus Bio-Ouest 6, Rue Alain Bombard 44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva com
|